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Abstract 
Background: Imatinib mesylate (IM) is the preferred treatment for the majority of patients with metastatic gastro-
intestinal stromal tumour (GIST). Low trough IM concentration (Cmin) values have been associated with poor clinical 
outcomes in GIST patients. However, there are few studies of repeated measurements of IM levels, and therapeutic 
drug monitoring is not yet a part of routine clinical practice. This study was conducted to reveal clinical scenarios 
where plasma concentration measurement of IM trough level (Cmin) is advantageous.
Methods: Patients with advanced GIST receiving IM were included from January 2011 to April 2015. Heparin plasma 
was collected at each follow-up visit. Ninety-six samples from 24 patients were selected for IM concentration meas-
urement. Associations between IM plasma concentration and clinical variables were analyzed by Students’ t test, 
univariate and multivariate linear regression analyses.
Results: The mean IM Cmin plasma concentrations for patients taking <400, 400 and >400 mg daily were 782, 1132 
and 1665 ng/mL, respectively (p = 0.010). High IM Cmin levels were correlated with age, low body surface area, low 
haemoglobin concentration, low creatinine clearance, absence of liver metastasis and no prior gastric resection 
in univariate analysis. In multivariate analysis age, gastric resection and liver metastasis were included in the final 
model. Eight patients had disease progression during the study, and mean IM levels were significantly lower at time 
of progression compared to the previous measurement for the same patients (770 and 1223 ng/mL, respectively; 
p = 0.020).
Conclusions: Our results do not support repeated monitoring of IM levels on a routine basis in all patients. However, 
we have revealed clinical scenarios where drug measurement could be beneficial, such as for patients who have 
undergone gastric resection, suspicion of non-compliance, subjectively reported side effects, in elderly patients and 
at the time of disease progression.
Keywords: Gastrointestinal stromal tumour, Drug monitoring, Imatinib, Plasma concentration
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Since the introduction of imatinib mesylate (IM) [1], the 
outcome of metastatic gastrointestinal stromal tumour 
(GIST) has improved considerably [2]. IM is an inhibi-
tor of receptor tyrosine kinases, including the stem cell 
factor receptor KIT and the platelet-derived growth 
factor receptor alpha (PDGFRA), the main drivers of 
tumour development in GIST [3]. Several clinical trials 
have demonstrated the efficacy and safety of IM, and it 
has become the treatment of choice for the majority of 
patients with metastatic GIST [2, 4, 5]. The median dura-
tion of response to IM in metastatic GIST is 29 months 
[2], with approximately 20% of the responses lasting 
10 years or more [6]. Still, most patients eventually pro-
gress on IM, requiring second- and third-line therapy 
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In patients with chronic myeloid leukaemia (CML) 
and GIST, pharmacokinetic (PK) studies have shown 
that IM has  >90% bioavailability following oral admin-
istration [8]. IM plasma concentration is influenced by 
various factors such age, body weight, body surface area 
(BSA), previous major gastric resection, white blood 
cell (WBC) count, haemoglobin, creatinine clearance, 
albumin, and alpha glycoprotein (AGP) levels [9–15]. 
A retrospective sub-study from the B2222 trial [4], the 
first trial showing safety and efficacy of IM in metastatic 
GIST patients, presented a significantly shorter time 
to progression in patients with IM trough levels (Cmin) 
below 1110  ng/mL at day 29 [16]. Additionally, a retro-
spective study in patients with CML in chronic phase 
reported that Cmin of IM could predict clinical outcome 
[13]. However, the optimal threshold value of IM Cmin 
has yet to be determined; both in patients with GIST 
and CML. A prospective PK study showed a significant 
decrease of approximately 30% in plasma IM concentra-
tion after 90 days of treatment [17], indicating that drug 
monitoring should preferentially be done after 3 months. 
This finding was recently supported by a study in real-
life practice, where Cmin was analysed after more than 
3 months of treatment, and concentrations above 760 ng/
mL were associated with longer progression-free survival 
(PFS) [18].
Although considerable inter-patient variability in IM 
plasma concentrations (40–60%) has been observed in 
several studies [15, 16], a fixed dose of 400  mg IM is 
the standard of care in patients with metastatic GIST 
[7]. Patients that progress on 400 mg/day and patients 
with KIT exon 9 mutations may benefit from increas-
ing the dose to 800 mg/day [2, 19, 20]. Treatment with 
400  mg IM is generally well tolerated, but patients 
still experience side effects such as anaemia, perior-
bital oedema, muscle cramps, and diarrhoea [2, 4, 5]. 
Several of these can be ameliorated with supportive 
measures, but some patients need dose modifications 
[21]. Compliance, i.e. adherence to self-administered 
drugs, is a general challenge for patients on any long-
term treatment, as also reported for patients with 
GIST [22]. However, the extent of non-compliance is 
often not known and might be a larger problem than 
expected. Altogether, there are several situations 
where IM plasma concentration measurements might 
have a considerable clinical impact in patients with 
metastatic GIST. However, at present, therapeutic 
drug monitoring (TDM) is not yet a part of routine 
clinical practice.
The aim of this study was to assess IM plasma con-
centration repeatedly over several years in a group of 
patients with metastatic GIST and thereby revealing 




Patients with GIST treated with IM were included from 
January 2011 to April 2015. Inclusion criteria were as fol-
lows: (1) histologically confirmed GIST; (2) treatment 
with IM initiated >90 days prior to study entry; (3) high-
risk tumour in the need of adjuvant IM, metastatic disease 
or inoperable primary tumour. Fifty-three patients were 
enrolled, of whom 19 received IM in a neoadjuvant/adju-
vant setting and 34 received IM for metastatic disease or 
inoperable primary tumour. For the present investigation 
we focused on patients in advanced or metastatic setting. 
We further excluded eight patients who had less than 
three available plasma samples and two patients where 
drug intake was not registered. Twenty-four patients 
were included in the final cohort. All patients attended 
regular 3- to 6-month follow-up visits and were seen by 
the same physician (ØSB). Radiological evaluation with 
computed tomography of the abdomen and pelvis was 
performed every 3–6  months depending on the clini-
cal scenario. Disease progression was objectively docu-
mented by an experienced radiologist. Secondary review 
using RECIST or CHOI criteria was not performed. Clin-
icopathological data were collected retrospectively by 
reviewing medical records. Body weight, height and bio-
chemical parameters were measured at the time of blood 
sampling for PK assessment. Creatinine clearance was 
estimated using the Cockcroft-Gault formula: estimated 
creatinine clearance  =  (140  −  age in years)  ×  (weight 
in kilograms) ×  (0.85 if female)/(72 −  serum creatinine) 
[23]. The study was approved by the Regional Ethics Com-
mittee (#S-06133a), and written informed consent was 
obtained from all patients. Patients were asked if they 
took the drug as prescribed, and divided into three groups 
based on drug compliance: Excellent compliance: Never 
forget to take IM; Intermediate compliance: Forget to take 
IM on occasions, less than once a week; Poor compliance: 
Not taking IM regularly with gaps for several days.
Sample collection
Three milliliter heparin plasma was collected at each fol-
low-up visit. Within 1 h of the collection, the blood sam-
ples were centrifuged in room temperature for 15 min at 
2500×g, and were stored at −20  °C until analysis. Sam-
ples were drawn in a routine clinical setting and not at 
the time of trough level. The time of drug intake was reg-
istered, and the validated Bayesian method developed 
by Gotta and colleagues [24] was used to extrapolate the 
measured concentrations to Cmin.
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Measurements of IM concentrations
The determination of the IM plasma concentrations 
followed the protocol as described in Ubhayasekhera 
et  al. [25]. IM standard was kindly provided by 
Novartis (Basel, Switzerland). All chemicals including 
internal standard (Trazodone) and ultrapure solvents 
were purchased from Sigma Aldrich (Stockholm, Swe-
den), unless otherwise stated. The stock solutions of 
IM and internal standard were prepared by dissolving 
methanol to obtain a final concentration of 1 mg/mL. 
Protein precipitation was applied as a sample pretreat-
ment. Twenty-five microliter of methanol containing 
1  µg/mL internal standard and 0.5  mL of methanol 
were added to 100 µL of plasma, shaken in 10 min and 
centrifuged for 10  min at 4  °C at 14,000g. The super-
natant was dried by vacuum centrifugation and the 
residue was reconstituted in 100 µL of 5% acetonitrile 
containing 0.1% formic acid. Aliquouts of 10  µL were 
injected into the LC–MS system. Chromatography 
and mass spectrometry was performed as previously 
described [25, 26].
Statistical analysis
All statistical analyses were performed by using SPSS 21.0 
(SPSS, Chicago, IL, USA). Differences in plasma concen-
trations between dose groups were assessed by Kruskal–
Wallis test. The IM Cmin values were log-transformed for 
the subsequent analyses. To assess the characteristics of 
the plasma samples in a homogenous cohort, we focused 
on the samples being drawn in patients taking 400  mg 
daily (n = 69). Correlations between IM Cmin and other 
variables were analysed by univariate linear regression 
(Pearson) and independent samples Student’s t test. Vari-
ables that showed significant correlations (p < 0.05) with 
IM Cmin in univariate analysis were included in a multi-
variate analysis using a multiple linear regression model 
with stepwise, backward elimination of variables. Cor-
relations were also tested using a more stringent linear 
mixed models effect analysis to take into account intra-
patient correlation. All tests were two-sided, and p values 
less than 0.05 were considered statistically significant.
Results
Patient characteristics
Ninety-six samples from 24 patients included in the study 
were analysed. There were 4 patients with three samples, 
16 patients with four samples and 4 patients with five 
samples. The median duration of IM treatment prior to 
the first sample was 25 months (range 3–77 months). The 
median time from the first sample to the last sample was 
32 months (range 4–48 months). All patients received IM 
for metastatic disease, except one patient who was medi-
cally inoperable and received IM for a large GIST in the 
small bowel. The median age was 69 years (range 33–88). 
The clinical and pathological features of all patients are 
listed in Table 1. Sixteen patients reported excellent com-
pliance, seven had intermediate compliance and one 
patient poor compliance. No patients experienced seri-
ous life-threatening adverse events. Seven patients had 
dose reductions: Six patients from 400 to 200  mg due 
to self-reported side effects and one patient from 800 to 
400 mg due to severe fluid retention and haematological 
toxicity.
Cmin plasma concentrations
Plasma samples were grouped according to the IM 
dose at time of sampling:  <400  mg group (100  mg: 
n = 2, 200 mg: n = 19), 400 mg (n = 69) and >400 mg 
(600  mg: n  =  1, 700  mg: n  =  1 and 800  mg: n  =  4). 
Mean ±  standard deviation values of IM Cmin plasma 
concentrations were 782  ±  589, 1132  ±  712 and 
1665  ±  924  ng/mL, respectively (Fig.  1a). The differ-
ence between the groups was statistically significant 
(p  =  0.010). Intra-patient and inter-patient variability 
was relatively large. The mean intra-patient variability 
Table 1 Baseline clinical and  pathological characteristics 




 Female 8 (33)
 Male 16 (67)
Primary tumour site
 Stomach 8 (33)
 Small bowel 13 (54)
 Rectum 2 (8)
 Unknown 1 (4)
Histological subtype
 Spindle cell 17 (71)
 Epitheloid 1 (4)
 Mixed 3 (13)
 ND 3
Mutation analysis
 KIT exon 11 18 (75)
 KIT exon 9 2 (8)
 PDGFRA exon 12 1 (4)
 Mutations not detected 2 (8)
 ND 1
Metastatic site
 Liver 13 (54)
 Intraperitoneal cavity 7 (29)
 Liver + intraperitoneal cavity 3 (13)
 No metastasis (inoperable primary tumour) 1 (4)
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(coefficient of variation) in patients taking 400 mg was 
36% and the highest intra-patient variability 69%, with 
maximum plasma concentration 1188 ng/mL and mini-
mum of 195 ng/mL. The mean inter-patient variability 
in patients taking 400  mg was 68%, with the highest 
measured concentration of 4491 ng/mL and the lowest 
concentration 195 ng/mL. Among the six patients with 
a dose reduction to 200  mg, two had relatively high 
mean plasma levels of 1418 and 2242 ng/mL, whereas 
the other four had mean plasma concentrations of 
387, 437, 565 and 521 ng/mL. Two patients started on 
200  mg and had mean plasma concentrations of 1704 
and 540 ng/mL.
Patient characteristics and Cmin plasma concentrations
Correlations between IM Cmin and clinical characteris-
tics were analysed in patients receiving the standard dose 
400 mg. The results presented below refer to the per-sample 
analysis. Linear mixed model effects analyses gave similar 
trends, although without reaching statistical significance. 
In univariate analysis, high IM Cmin was significantly cor-
related with age (β = 0.303, p = 0.012), BSA (β = −0.300, 
p =  0.010), low haemoglobin concentration (β = −0.290, 
p  =  0.016), low creatinine clearance (β  =  −0.234, 
p =  0.050), but not with albumin (p =  0.061) or calcium 
level (p  =  0.999), tumour diameter (p  =  0.368), gender 
(p = 0.915), WBC (p = 0.832) or platelet count (p = 0.816).
Fig. 1 Boxplots showing imatinib mesylate (IM) trough levels (Cmin). Boxes indicate the median, the 25th and 75th percentile, and whiskers represent 
maximum and minimum values. Outliers are censored. Mean Cmin values ± standard deviations are indicated for each category. a IM Cmin levels 
categorised according to dose groups: <400 mg (n = 21), 400 mg (n = 69) and >400 mg (n = 6). b IM Cmin levels categorised according to gastric 
resection (n = 28) or not (n = 41). c IM Cmin levels categorised according to presence (n = 46) or absence (n = 23) of liver metastases. d IM Cmin 
levels categorised according to whether patients had experienced disease progression or not. For patients with disease progression (right panel), 
the left box represents the last plasma samples at stable disease and the box to the right represents the plasma samples at the time of progressive 
disease. For patients with stable disease (left panel), the left box represents the second last plasma samples and the box to the right represent the last 
plasma samples drawn
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Nine patients (38%) had undergone subtotal or total 
gastrectomy, and IM Cmin was significantly lower in 
these patients (865  ±  476  ng/mL; n  =  28) than in 
plasma samples from patients without gastric surgery 
(1315 ± 790 ng/mL; n = 41; p = 0.015) (Fig. 1b). Further-
more, IM Cmin was significantly lower in the plasma sam-
ples from patients with liver metastases (1003 ± 710 ng/
mL, n = 46) compared to patients without liver metasta-
ses (1390 ± 657 ng/mL, n = 23; p = 0.025) (Fig. 1c).
Multivariate analysis was performed including varia-
bles that were associated with IM Cmin in univariate anal-
ysis in the 400 mg group. Gastric resection (p = 0.021), 
age (p = 0.049) and liver metastases (p = 0.010) were the 
covariates significantly associated with IM Cmin.
Disease progression and Cmin plasma concentrations
Eight patients had disease progression during the study. 
In seven of these IM Cmin concentrations decreased at 
the time of progression compared to the previous meas-
urement. The mean IM Cmin concentration at the time of 
progression was 770 ± 487 ng/mL, and in the last sam-
ple from the time of stable disease from the same patients 
1223 ± 796 ng/mL (p = 0.021; Student’s test). In compar-
ison, there was no statistically significant difference in IM 
Cmin concentration between the two last plasma samples 
collected in patients with stable disease throughout the 
study (1161 ± 658 versus 1115 ± 511 ng/mL) (Fig. 1d).
Discussion
The role of IM Cmin measurements in optimizing thera-
peutic efficacy in GIST is still investigational, despite pre-
liminary estimates of IM blood levels that are associated 
with improved clinical outcomes (Cmin  >  1110  ng/mL) 
[16]. In this study, we assessed Cmin in a group of patients 
over several years trying to determine whether there are 
clinical scenarios where measurements of IM Cmin could 
be advantageous. To the best of our knowledge this is the 
first study in metastatic GIST with repeated measure-
ments of Cmin plasma concentrations including samples 
at the time of documented progression.
Low IM Cmin was associated with major gastrectomy 
in both univariate and multivariate analysis, which is 
consistent with previous findings [14]. IM tablets dis-
solve more rapidly at pH 5.5 or less [8], and lack of gas-
tric acid secretion may explain the lower concentration 
in such patients. Many patients with metastatic GIST 
have previously undergone surgery for a primary gastric 
GIST and one might speculate that such patients could 
possess an increased risk of sub-therapeutic IM plasma 
levels and subsequently a less favourable disease out-
come. In our cohort, only eight patients had disease pro-
gression, of which three had undergone gastric resection. 
Thus, analysing the prognostic impact of gastric surgery 
is impossible due to small patient numbers. Still, a more 
individualized drug dosage based on IM plasma concen-
trations may be beneficial in patients with prior gastric 
surgery.
Interestingly, in the current study patients with liver 
metastases had low IM Cmin compared to patients with-
out liver metastases. A previous study has shown that IM 
clearance is not affected by low volume liver disease [17], 
and it thus seems unlikely that the liver metastases per se 
affect IM metabolism in our patients. We are not aware 
of studies that have reported differences in IM plasma 
concentration in patients with or without liver metasta-
ses, and this issue could be of interest for further studies.
Older patients had higher plasma concentrations in 
our cohort. The well-known decline of organ functions 
and increased prevalence of comorbidity and concomi-
tant medication among elderly patients may influence the 
pharmacokinetics and pharmacodynamics of IM. We did 
not prospectively register concomitant medications or 
co-occurring medical conditions, and are thus not able 
to discern the role of these factors separately. Our results 
could suggest that individual dosing supported by IM 
plasma concentration measurement could be even more 
useful in elderly patients, to balance side effects and anti-
tumour efficacy more precisely.
Although there were no serious adverse events in our 
study, dose reduction due to subjective side effects were 
mandatory in seven patients. Two of these patients had 
relatively high Cmin on 200 mg, suggesting that for some 
patients this dose is enough to ensure optimal therapeu-
tic plasma levels of IM. The four other patients had low 
levels suggesting that patient-reported side effects are not 
necessarily associated with high plasma concentrations. 
Few studies have explored the relationship between IM 
plasma concentration and side effects. One study showed 
that the occurrence and number of side effects correlated 
with IM total and free plasma concentrations in GIST 
patients [27], but further studies on relations between 
concentration and toxicity are warranted. Unfortunately, 
we did not register side effects in a formal and prospec-
tive manner. However, measuring Cmin concentrations in 
patients experiencing subjective side effects (e.g. muscle 
cramps, dizziness, fatigue etc.) that limit daily activity 
may help to determine whether it is safe to modify the 
dose of IM.
The relatively large inter- and interpatient variability 
in our study compared to other real-life cohorts [14, 18] 
could be explained by lack of compliance. Although oral 
cancer therapies offer patients the convenience of self-
administration at home, evidence show that adherence to 
these therapies is far from optimal [28, 29]. The BFR14 
Study evaluated the effect of IM interruption in respond-
ing patients (complete response, partial response, or 
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stable disease) after different periods of treatment (1, 3 
and 5  years), and results from the study indicated that 
discontinuation of IM is associated with rapid progres-
sion [30–32]. Therefore, maintaining proper adherence 
may be of great significance and drug monitoring could 
potentially improve compliance to therapy.
Interestingly, we found a decrease in Cmin plasma 
concentration at the time of disease progression, which 
might explain loss of disease control in certain patients. 
Measurements of IM Cmin in case of progressive disease 
could therefore be indicated if lack of patient compliance 
has been ascertained. A sub-therapeutic drug level at the 
prescribed dose could suggest that increasing the dose 
would be of clinical benefit, in particular in the absence 
of secondary KIT or PDGFRA mutations. Studies com-
paring 400 with 800  mg IM daily in advanced disease 
showed no clinical benefit of IM 800 mg daily, except for 
tumours with KIT exon 9 mutations [33]. Despite this, 
dose escalation to 800 mg can be beneficial in up to 30% 
of patients upon disease progression on 400  mg [2, 19, 
20]. IM plasma concentration measurements have not 
been performed in dose escalation studies, and perhaps 
only patients with sub-therapeutic IM levels will ben-
efit from this strategy, whereas the remainder should be 
offered second-line therapy.
Total IM plasma concentration was measured in our 
study. Another option is to measure free drug concentra-
tions; i.e. the pharmacologically active fraction not bound 
by albumin or AGP. The area under the PK curve (AUC) 
for IM, which can either be measured directly or as the 
correction of the total drug concentration for binding 
to AGP, may provide a better surrogate for cellular drug 
exposure than total IM concentration [15, 26]. Further-
more, IM concentration measurement in the cytoplasm of 
the tumour cells could even more precisely predict target 
inhibition and clinical efficacy. A new approach to meas-
urement of intracellular levels of IM in an in vivo setting 
has been developed, and there were large variation in IM 
concentrations between plasma, adipose tissue, and dif-
ferent sites within a given tumour [34]. Although only 
three patients were included in the latter study, this high-
lights the importance of further clinical investigations on 
measurements of intracellular IM levels in GIST tissues to 
understand their possible impact on patient outcome.
Among the limitations of this study are the retrospec-
tive registration of the majority of the clinical data and 
side effects. We neither did review of the radiology nor 
the pathology, but experienced sarcoma radiologists and 
pathologists at a major reference centre had already con-
firmed the diagnostic work-up at start of IM, including 
analyses of KIT and PDGFRA mutations that were found 
in all patients except three. Furthermore, patients with <3 
plasma samples were excluded, and median treatment 
duration of IM before inclusion was 25  months. Even 
though patients were not excluded due to progressive dis-
ease, a bias towards patients without progression could 
have occurred. Moreover, the plasma samples were not 
drawn at trough time, but a validated method to extrap-
olate the samples to trough was used [25]. Even though 
these issues in general would be considered as shortcom-
ings, they reflect well a routine oncology practice, and 
our findings could therefore easily be transferred to a 
routine clinical setting.
In conclusion, our results do not support repeated 
monitoring of IM levels on a routine basis in all patients. 
However, we have revealed clinical scenarios where drug 
measurement could be beneficial, such as for patients 
who have undergone gastric resection, suspicion of non-
compliance, subjectively reported side effects, in elderly 
patients and at the time of disease progression. Whether 
dose escalation could be beneficial at disease progression 
for patients with low IM plasma concentration should be 
further studied.
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